Hamburg, Germany, April 2026 — Evotec has appointed Claire Hinshelwood as Chief Financial Officer (CFO), as the company continues its transformation journey and sharpens its focus on sustainable, profitable growth. In this role, she will lead the global finance function, strengthen governance, and support Evotec’s long-term value creation strategy.
Claire Hinshelwood brings over three decades of global finance leadership experience across healthcare, chemicals, manufacturing, and building materials. Most recently, she served as Group Chief Financial Officer at BMI Group, where she led a strategic turnaround, strengthened liquidity, improved operating margins, and rebuilt finance and governance frameworks to enhance business resilience.
Prior to that, she held the role of Global Head of Finance Operations at Novartis, where she led end-to-end finance operations across multiple geographies, driving transformation initiatives, strengthening governance and compliance frameworks, and overseeing large-scale financial reporting and systems programs.
She also spent nearly 15 years at Syngenta, where she held multiple senior leadership roles across Asia Pacific, Eastern Europe, and Latin America, including Head of Finance Asia Pacific. During this time, she played a key role in enterprise strategy, capital markets activities, investor relations, and large-scale transformation programs across regions.
Earlier in her career, Claire Hinshelwood built strong operational finance expertise during her tenure with Hillshire Brands, laying the foundation for her global leadership journey.
With extensive international experience and a proven track record in transformation, governance, and capital discipline, she steps into the CFO role at a pivotal time for Evotec, well positioned to guide the organization’s next phase of operational execution and growth.
Evotec is a global biotechnology company focused on advancing drug discovery and development through collaborative and integrated approaches. Its Pipeline Co-Creation model enables partnerships with pharmaceutical companies, biotech firms, and research organizations across all stages—from target discovery to clinical proof of concept and commercial manufacturing.
With a strong focus on data, AI, and scientific innovation, and a global team of over 4,000 scientists, Evotec continues to accelerate the development of innovative medicines aimed at improving patient outcomes worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
